The Biotech Stock Smashing 2025!

Dear Trader, 

This little-known medtech company just got a $32.50 price target!
The medical device market is set to grow from over $500B to nearly $890B by 2032.
Standing out in this fast-growing space is BioStem Technologies (OTC: BSEM), a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies.
The company is driving innovation in the wound care space and excitingly enhanced its intellectual property portfolio with the issuance of a significant patent.
The is the first and only patent granted for use in tabular fenestrated allografts, which will support the company’s commercial efforts and expand its IP portfolio.
With 27 patents pending and 42 issued, BioStem has a strong portfolio across the wound care landscape that will protect the company as it advances in the market.
Not only is BSEM reporting quarter after quarter of record revenues, but full year net revenue for 2024 is anticipated to be $301.8M, representing a stellar 1,702% growth since fiscal year 2023! 
With a new clinical trial launched at the start of 2025 and the company gearing up to uplist to the NASDAQ exchange, it may be no surprise that BSEM has been given a $32.50 price target from Zacks Small Cap Research!
The firm wrote in its last price target upgrade, “We reiterate our belief the BSEM is still underpriced even after its recent move higher and continues to represent a good opportunity at recent prices for investors to get in before what we believe will be a more aggressive move higher in the not-too-distant future.
The vision management has for the company’s products and the focus they are using to deliver results are encouraging and are now being rewarded by increased demand. As such, we urge investors to take a good look at BSEM.”
Click here to get all the details on this up and coming stock!
-Huge Alerts Team